KLOW
80 mg / 3 ml · Injectable pen
Peptide blend · pen presentation
The HAVO KLOW pen presentation, with 80 mg total content in 3 ml. Individual ingredients and proportions await confirmation from the laboratory.
Overview
The supplied HAVO packaging identifies KLOW 80 mg / 3 ml. It does not establish the quantity of each constituent.
Mechanism & scientific context
The Oxygen KLOW pen reference lists BPC-157, TB-500, GHK-Cu and KPV. This describes another brand; it does not confirm the composition, proportions or combined biological action of HAVO KLOW.
Indications & evidence
No therapeutic indication is established here for this HAVO blend. Claims about individual peptides cannot establish the effectiveness of an unconfirmed combination.
Presentation & box contents
Pen presentation with a declared volume of 3 ml. The amount shown is the total content, not a dose per injection. Needle compatibility, dose settings and included accessories must be checked against the instructions supplied with the product.
Contraindications
A product-specific assessment requires the complete formula, excipients and manufacturer documentation. A reliable contraindication list cannot be supplied from the name KLOW alone.
Precautions
Confirm every ingredient and its amount with the laboratory before any clinical assessment. Do not infer tolerability, interactions or dosing from another brand’s blend.
Storage & handling
Keep refrigerated between 2°C and 8°C, as specified by HAVO for this presentation. Follow the product label for expiry and the period after first use. No room-temperature allowance or in-use shelf life has been established here. If frozen, damaged or exposed to temperatures outside this range, contact the laboratory before use.
Scientific information about an ingredient does not establish approval, efficacy or equivalence of this HAVO presentation. Consult the local product documentation and a qualified healthcare professional. This summary is not a prescribing guide.